# OnCo record pd-l1-tps (biomarker). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/biomarkers/pd-l1-tps/>
  a schema:MedicalTest ;
  onco:kind "biomarker" ;
  schema:identifier "pd-l1-tps" ;
  schema:name "PD-L1 TPS (tumour proportion score)"@en ;
  schema:alternateName "PD-L1 TPS"@en, "TPS"@en, "tumor proportion score"@en, "tumour proportion score"@en, "TPS >= 1%"@en, "TPS >= 50%"@en, "PD-L1 TPS 50"@en, "PD-L1 high"@en, "PD-L1 ≥50%"@en, "TPS≥50%"@en, "TPS≥1%"@en ;
  schema:description "TPS is the share of tumour cells whose membrane stains for PD-L1, ignoring immune cells. In lung cancer it decides whether pembrolizumab or cemiplimab can be given alone: 1 percent opens the door, 50 percent is where single-agent treatment is strongest."@en ;
  schema:url <https://onco.cc/biomarkers/pd-l1-tps/> ;
  schema:dateModified "2026-09-23"^^xsd:date ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9333c79b-d487-4538-a9f0-71b91a02b287>, <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4347ae1f-d397-4f18-8b70-03897e1c054a> ;
  onco:tag "biomarker", "pd-l1" ;
  onco:related <https://onco.cc/biomarkers/pd-l1-cps/>, <https://onco.cc/biomarkers/pd-l1-ic-score/>, <https://onco.cc/biomarkers/pd-l1-tc-score/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/lung-cancer/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/cemiplimab/>, <https://onco.cc/drugs/dako-pd-l1-22c3-pharmdx/>, <https://onco.cc/drugs/ventana-pd-l1-sp263/> ;
  onco:terms <https://onco.cc/terms/tps/>, <https://onco.cc/terms/pd-l1-testing/>, <https://onco.cc/terms/ihc/> .